PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.

被引：1
|
作者：
Villagrasa, Patricia
Gonzalez, Xavier
Oliveira, Mafalda
Vazquez, Josep
De La Pena, Lorena
Llobet-Canela, Marta
Prat, Aleix
Ciruelos, Eva
机构：
[1] SOLTI Breast Canc Res Grp, Barcelona, Spain
[2] Quiron Dexeus Univ Hosp, Translat Res Unit, Dr Rosell Oncol Inst, Barcelona, Spain
[3] Vall dHebron Univ Hosp VHIO, Barcelona, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Hosp Univ 12 Octubre, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps642
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS642
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer
    Shagisultanova, Elena
    Diamond, Jennifer
    Stopeck, Alison
    Pusztai, Lajos
    O'Regan, Ruth
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    McSpadden, Tessa
    Borakove, Michelle
    Shedin, Troy
    Kabos, Peter
    Borges, Virginia
    CANCER RESEARCH, 2018, 78 (04)
  • [42] Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study
    Ciruelos, Eva
    Pascual, Tomas
    Oliveira, Mafalda
    Escriva-de-Romani, Santiago
    Pernas, Sonia
    Pare, Laia
    Adamo, Barbara
    Martinez, Eduardo
    Cortes, Javier
    Perello, Antonia
    Galan, Maria
    Mele, Mireia
    Tolosa, Pablo
    Gonzalez-Farre, Blanca
    Galvan, Patricia
    Canes, Jordi
    Nuciforo, Paolo
    Gonzalez, Xavier
    Villagrasa, Patricia
    Prat, Aleix
    CANCER RESEARCH, 2022, 82 (04)
  • [43] Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+HER2+breast cancer (PALTAN)
    Ademuyiwa, Foluso O.
    Northfelt, Donald
    O'Connor, Tracey
    Levine, Ellis
    Luo, Jingqin
    Tao, Yu
    Hoog, Jeremy
    Laury, Marie
    Summa, Tracy
    Hammerschmidt, Trish
    Guo, Zhanfang
    Frith, Ashley
    Weilbaecher, Katherine
    Opyrchal, Mateusz
    Aft, Rebecca
    Clifton, Katherine
    Suresh, Rama
    Bagegni, Nusayba
    Hagemann, Ian S.
    Ma, Cynthia X.
    CANCER RESEARCH, 2022, 82 (04)
  • [44] A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
    Bora Lim
    Rashmi K. Murthy
    Jangsoon Lee
    Summer A. Jackson
    Toshiaki Iwase
    Darren W. Davis
    Jie S. Willey
    Jimin Wu
    Yu Shen
    Debu Tripathy
    Ricardo Alvarez
    Nuhad K. Ibrahim
    Abenaa M. Brewster
    Carlos H. Barcenas
    Powel H. Brown
    Sharon H. Giordano
    Stacy L. Moulder
    Daniel J. Booser
    Jeffrey A. Moscow
    Richard Piekarz
    Vicente Valero
    Naoto T. Ueno
    British Journal of Cancer, 2019, 120 : 1105 - 1112
  • [45] A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
    Lim, Bora
    Murthy, Rashmi K.
    Lee, Jangsoon
    Jackson, Summer A.
    Lwase, Toshiaki
    Davis, Darren W.
    Willey, Jie S.
    Wu, Jimin
    Shen, Yu
    Tripathy, Debu
    Alvarez, Ricardo
    Ibrahim, Nuhad K.
    Brewster, Abenaa M.
    Barcenas, Carlos H.
    Brown, Powel H.
    Giordano, Sharon H.
    Moulder, Stacy L.
    Booser, Daniel J.
    Moscow, Jeffrey A.
    Piekarz, Richard
    Valero, Vicente
    Ueno, Naoto T.
    BRITISH JOURNAL OF CANCER, 2019, 120 (12) : 1105 - 1112
  • [46] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer
    Kalinsky, Kevin
    Chi, Dow-Chung
    Lee, Shing Mirn
    Adelson, Kerin B.
    Crew, Katherine D.
    Chuang, Ellen
    Makower, Della
    Hershman, Dawn L.
    Califano, Andrea
    Silva, Jose
    Maurer, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer
    Yamamoto, Harukaze
    Ando, Masashi
    Aogi, Kenjiro
    Iwata, Hiroji
    Tamura, Kenji
    Yonemori, Kan
    Shimizu, Chikako
    Hara, Fumikata
    Takabatake, Daisuke
    Hattori, Masaya
    Asakawa, Takashi
    Fujiwara, Yasuhiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 12 - 18
  • [48] Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer
    O'Shaughnessy, Joyce
    Glidden, Andrea
    Locke, Tracy
    Scales, Amy
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study
    Modi, Shanu
    FUTURE ONCOLOGY, 2021, 17 (26) : 3415 - 3423
12345